A Retrospective Study on Colistin Nephrotoxicity in Pediatric Onco-hematology Patients

Abstract

Background There are limited data on the safety of colistin in pediatric patients, especially from developing countries.

Methods This is a retrospective analysis of pediatric patients with carbapenem-resistant gram-negative bacteremia treated with colistin from an onco-hematology center in India. Nephrotoxicity was assessed using the pRIFLE criteria.

Results Out of the 21 patients treated with colistin, 13 received concomitant nephrotoxic agents. Mean dose of colistin used was 141,050 IU/kg colistin methane sulfonate (CMS; 4.23 mg/kg, colistin base activity [CBA] = 11.28 mg/kg CMS) in three divided doses and mean duration was 7.85 days. None of the patients in our study developed nephrotoxicity according to the pRIFLE criteria.

Conclusion There was no colistin-induced nephrotoxicity in our case series.

Keywords

colistin - nephrotoxicity - CRGNB - carbapenem-resistant gram-negative bacteremia

• References

• 1 Ghafur A. A Call to action: For the attention of oncologists!. South Asian J Cancer 2012; 1 (1) 48-49
• 2 Rosolem MM, Rabello LS, Lisboa T , et al. Critically ill patients with cancer and sepsis: clinical course and prognostic factors. J Crit Care 2012; 27 (3) 301-307
• 3 Turkoglu M, Mirza E, Tunçcan OG , et al. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality. J Crit Care 2011; 26 (5) 460-467
• 4 Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME. Predictors of mortality in patients with infections due to multi-drug resistant gram negative bacteria: the study, the patient, the bug or the drug?. J Infect 2013; 66 (5) 401-414
• 5 Ghafur A, Vidyalakshmi PR, Murali A, Priyadarshini K, Thirunarayan MA. Emergence of Pan-drug resistance amongst gram negative bacteria! The first case series from India. JMID 2014; 4 (3) 86-91
• 6 Tamma PD, Newland JG, Pannaraj PS , et al. The use of intravenous colistin among children in the United States: results from a multicenter, case series. Pediatr Infect Dis J 2013; 32 (1) 17-22
• 7 Kumar PP, Giri SR, Shaikh FA, Panigrahy N, Chirla D. Safety and efficacy of intravenous colistin in children. Indian Pediatr 2015; 52 (2) 129-130
• 8 Ghafur A, Priyadarshini K, Vidyalakshmi PR. “Clinical Profile of Carbapenem Resistant Bacteraemia Among Paediatric Population- First Clinical Study from India”. A-534–0002–01455 Entitled at The 31st Annual Meeting ofthe European Society for Paediatric Infectious Diseases. May 28-June 1 2013-Milan, Italy
• 9 Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int 2007; 71 (10) 1028-1035
• 10 Goverman J, Weber JM, Keaney TJ, Sheridan RL. Intravenous colistin for the treatment of multi-drug resistant, gram-negative infection in the pediatric burn population. J Burn Care Res 2007; 28 (3) 421-426
• 11 Rosanova M, Epelbaum C, Noman A , et al. Use of colistin in a pediatric burn unit in Argentina. J Burn Care Res 2009; 30 (4) 612-615
• 12 Jajoo M, Kumar V, Jain M, Kumari S, Manchanda V. Intravenous colistin administration in neonates. Pediatr Infect Dis J 2011; 30 (3) 218-221
• 13 Paksu MS, Paksu S, Karadag A , et al. Old agent, new experience: colistin use in the paediatric intensive care unit—a multicentre study. Int J Antimicrob Agents 2012; 40 (2) 140-144
• 14 Celebi S, Hacimustafaoglu M, Koksal N, Ozkan H, Cetinkaya M. Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients. Pediatr Int 2010; 52 (3) 410-414
• 15 Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2010; 35 (3) 297-300
• 16 Iosifidis E, Antachopoulos C, Ioannidou M , et al. Colistin administration to pediatric and neonatal patients. Eur J Pediatr 2010; 169 (7) 867-874
• 17 Falagas ME, Sideri G, Vouloumanou EK, Papadatos JH, Kafetzis DA. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J 2009; 28 (2) 123-127
• 18 Pogue JM, Lee J, Marchaim D , et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53 (9) 879-884
• 19 Ozkan G, Ulusoy S, Orem A , et al. How does colistin-induced nephropathy develop and can it be treated?. Antimicrob Agents Chemother 2013; 57 (8) 3463-3469
• 20 Falagas ME, Sideri G, Vouloumanou EK, Papadatos JH, Kafetzis DA. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J 2009; 28 (2) 123-127
• 21 Pintado V, San Miguel LG, Grill F , et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 2008; 56 (3) 185-190
• 22 Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev 2008; 21 (3) 449-465
• 23 Li J, Nation RL, Turnidge JD , et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006; 6 (9) 589-601
• 24 Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10 (1) R27